Evommune, Inc. raised $115 million in a Series C led by RA Capital Management and Sectoral Asset Management to support the clinical development of its EVO756 and EVO301 programs.
Oct 31, 2024•11 months ago
Amount Raised
$115 Million
Round Type
series c
Palo AltoBiotechnologyHealth CareInvestors
Verition Fund ManagementSymbiosisAmplitude VenturesAndera PartnersEqt Life SciencesPivotal Bio Venture PartnersAllostery Investments LpFem Health VenturesBeiersdorf Venture CapitalNext Bio CapitalAdar1 Capital ManagementRtw InvestmentsLongwood FundAvego Bioscience CapitalMarshall WaceB CapitalSectoral Asset ManagementRa Capital Management
Description
Evommune, Inc. has completed a $115 million Series C financing to advance its clinical-stage pipeline for chronic inflammatory diseases. The funding, co-led by RA Capital Management and Sectoral Asset Management, will facilitate clinical development and data readouts expected in the coming years.
FundzWatch™ Score
68
Medium Activity
Buyer Intent Analysis
Get personalized insights on buying likelihood
Funding Insights
Based on industry dataVC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech